Meloxicam Shortage: What Providers and Prescribers Need to Know in 2026

Meloxicam remains one of the most prescribed NSAIDs in primary care, rheumatology, and orthopedic settings. As of 2026, it is not on the FDA's official drug shortage list — but providers are still fielding calls from patients who cannot fill their prescriptions at local pharmacies. Understanding the supply landscape, clinical implications, and available options will help you manage these situations effectively.

Current Supply Status: What the Data Shows

As of 2026, generic meloxicam tablets (7.5 mg and 15 mg) are manufactured by multiple companies and are nationally available. The brand-name Mobic was discontinued by Boehringer Ingelheim; however, generic substitution is clinically appropriate for the tablet formulation.

Important caveat: The FDA has stated that MOBIC Tablets have not shown equivalent systemic exposure to other approved oral meloxicam formulations. Different formulations (tablets, capsules like Vivlodex, ODTs, oral suspension) should not be considered therapeutically interchangeable at equivalent mg strengths without prescriber authorization. This is relevant when patients ask about switching to a different meloxicam formulation during a tablet stockout.

The Oral Suspension Situation

The meloxicam oral suspension (7.5 mg/5 mL), used for juvenile idiopathic arthritis in children 2 years and older, is manufactured by fewer generic companies than the tablets and is not stocked at all retail pharmacies. Pediatric patients with JIA may face more consistent access challenges than adult patients on tablets. Providers should be prepared to direct families to call ahead or use a pharmacy locator service.

Clinical Implications of Patients Missing Doses

For patients with osteoarthritis, interrupting meloxicam therapy typically means a return of pain and reduced functional capacity, but does not typically cause disease progression over days to weeks. For patients with active rheumatoid arthritis, however, loss of NSAID coverage can accelerate inflammatory flares, which may be more difficult to regain control of. The clinical urgency of sourcing meloxicam quickly is greater in RA patients.

Therapeutic Substitution: When and How to Switch

If a patient cannot locate meloxicam after a reasonable search, a short-term therapeutic substitution is clinically reasonable. The following NSAID options are generally considered appropriate substitutes, with the right choice depending on patient-specific factors:

Celecoxib (Celebrex) 100–200 mg once or twice daily: Preferred for patients with GI risk (history of ulcers, GERD). COX-2 selective; faster onset than meloxicam. Generic available. Note: similar cardiovascular risk profile to meloxicam.

Naproxen 375–500 mg twice daily: Often preferred when minimizing cardiovascular risk is paramount; evidence from large network meta-analyses suggests naproxen may carry a lower CV risk than some other NSAIDs. Available OTC at lower doses.

Ibuprofen 400–800 mg three times daily: Widely available and effective for OA and RA symptom management. Greater dosing frequency than meloxicam. Higher adherence challenges for chronic disease management.

Diclofenac (topical or oral): Topical Voltaren Gel is useful for localized OA (e.g., knee). Oral diclofenac is effective but requires 2–3 daily doses and carries a higher cardiovascular risk vs. naproxen per some analyses.

Key Prescribing Reminders for All NSAIDs

All oral NSAIDs carry the same FDA Boxed Warnings for cardiovascular thrombotic events and GI bleeding. No therapeutic alternative eliminates these risks.

Avoid NSAIDs at ≥30 weeks gestation (risk of premature ductus arteriosus closure). Use with caution at 20–29 weeks.

Avoid in patients with severe renal impairment (eGFR <30), advanced heart failure, and those who have recently had a MI or CABG surgery.

Monitor renal function, blood pressure, and for signs of GI bleeding in any patient on long-term NSAID therapy.

Helping Patients Navigate Pharmacy Access

When patients contact your office unable to find their prescription, directing them to a pharmacy locator service can save significant time. medfinder for providers allows practices to help patients quickly identify which pharmacies near them have the medication in stock, reducing unnecessary calls to your clinic and improving adherence.

Documenting Therapeutic Substitution

When switching a patient to an alternative NSAID due to access issues, document the clinical rationale clearly in the chart. Include: the reason for substitution, the alternative selected, any relevant risk factor assessment (cardiovascular, GI, renal), and the plan to return to the original medication if/when supply is restored. This supports continuity of care and appropriate follow-up monitoring.

For a complete workflow guide on helping patients find their medications, see: How to Help Your Patients Find Meloxicam In Stock: A Provider's Guide.